ONO MSA
Brief description of study
Based on its mechanism of action, ONO-2808 has the potential to provide symptomatic improvement and modify disease progression in patients with MSA by promoting remyelination and reducing pathogenic CNS -synuclein accumulation. This initial study of ONO-2808 in MSA patients will generate data to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of 3 doses of ONO-2808 compared to placebo.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
